Charles J. Sande

H. Goldstein, John Wright, P. Hardelid, 2021, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

Admission to hospital for bronchiolitis in England: trends over five decades, geographical variation and association with perinatal characteristics and subsequent asthma

M. Goldacre, A. Pollard, R. Parslow, 2015, Archives of Disease in Childhood.

Presumed Risk Factors and Biomarkers for Severe Respiratory Syncytial Virus Disease and Related Sequelae: Protocol for an Observational Multicenter, Case-Control Study From the Respiratory Syncytial Virus Consortium in Europe (RESCEU).

P. Klenerman, T. Heikkinen, E. Sanders, 2020, The Journal of infectious diseases.

Defining the vaccination window for respiratory syncytial virus (RSV) using age-seroprevalence data for children in Kilifi, Kenya

D. Nokes, P. Munywoki, J. Nyiro, 2017, PloS one.

Respiratory syncytial virus: diagnosis, prevention and management

C. Green, Charles J. Sande, S. Drysdale, 2019, Therapeutic advances in infectious disease.

Absence of Association between Cord Specific Antibody Levels and Severe Respiratory Syncytial Virus (RSV) Disease in Early Infants: A Case Control Study from Coastal Kenya

D. Nokes, P. Munywoki, J. Nyiro, 2016, PloS one.

Non-specific immunological effects of selected routine childhood immunisations: systematic review

A. Pollard, M. Voysey, U. Uhlig, 2016, British Medical Journal.

Antibodies in lymphocyte supernatants can distinguish between neutralising antibodies induced by RSV vaccination and pre-existing antibodies induced by natural infection.

A. Pollard, A. Vitelli, A. Thompson, 2018, Vaccine.

Development of respiratory syncytial virus (RSV) vaccines for infants.

Charles J. Sande, Hannah E Gerretsen, Charles J Sande, 2017, The Journal of infection.

Priorities for developing respiratory syncytial virus vaccines in different target populations

A. Pollard, C. Rollier, C. Green, 2020, Science Translational Medicine.

Novel genetically-modified chimpanzee adenovirus and MVA-vectored respiratory syncytial virus vaccine safely boosts humoral and cellular immunity in healthy older adults

A. Nicosia, P. Klenerman, A. Pollard, 2019, Journal of Infection.

Quantifying maternally derived respiratory syncytial virus specific neutralising antibodies in a birth cohort from coastal Kenya

J. Scott, D. Nokes, P. Munywoki, 2015, Vaccine.

Untargeted analysis of the airway proteomes of children with respiratory infections using mass spectrometry based proteomics

D. Nokes, J. Berkley, D. Nokes, 2018, Scientific Reports.

In-silico immune cell deconvolution of the airway proteomes of infants with pneumonia reveals a link between reduced airway eosinophils and an increased risk of mortality

Charles J. Sande, M. Mutunga, C. Sande, 2019, bioRxiv.

Agreement between ELISA and plaque reduction neutralisation assay in Detection of respiratory syncytial virus specific antibodies in a birth Cohort from Kilifi, coastal Kenya.

J. Scott, D. Nokes, P. Munywoki, 2019, Wellcome open research.

The association between age and the development of respiratory syncytial virus neutralising antibody responses following natural infection in infants

P. Cane, D. Nokes, Charles J. Sande, 2014, Vaccine.

Scott, JA; Nokes, DJ (2016) Absence of Association between Cord Specific Antibody Levels and Severe Respiratory Syncytial Virus (RSV) Disease in Early Infants: A Case Control

D. Nokes, P. Munywoki, J. Nyiro, 2019 .

Group- and Genotype-Specific Neutralizing Antibody Responses Against Respiratory Syncytial Virus in Infants and Young Children With Severe Pneumonia

P. Cane, G. Medley, D. Nokes, 2012, The Journal of infectious diseases.

Comprehensive profiling of antibodies against multiple infectious diseases in serum and the airway mucosa using synthetic peptide-based linear epitope microarrays

D. Nokes, C. Green, Charles J. Sande, 2018 .